CA-SENTRY
Sentry , the market leader in developer-first application monitoring, today announced it has raised $90 million for its Series E, bringing the company’s total funding to $217 million and valuing the company at more than $3 billion. This round was co-led by BOND and Accel , with participation from existing investor New Enterprise Associates (NEA) and new investor K5 Global . The new capital will help fuel the company’s long-term growth for product development, hiring, and global expansion in Europe.
Sentry is reshaping application performance monitoring (APM) by directly addressing the developer experience gap. With the proliferation of applications, languages, and frameworks, Sentry empowers any developer or development team to solve issues in production code by using one tool to monitor for errors, performance, and health across mobile, desktop, and IoT, and across any industry or vertical.
In the past year, the company saw rapid growth driven by customer adoption of Error and Performance Monitoring, with net expansion of annual recurring revenue (ARR) increasing by 130%+ year over year. Sentry now processes 790+ billion events per month, with mobile events increasing by more than 100% year over year.
“Our singular focus on developers, combined with the depth of our platform across 100+ languages, allows us to uniquely solve developer problems for every customer and software environment,” said Milin Desai, CEO at Sentry. “Revenue has more than tripled in just over two years, and our team will continue to be laser-focused on providing engineering organizations with the ability to ship better code faster.”
"Our customers expect constant improvements to the product experience along with new feature updates, and without any disruptions to their current workflows,” said Kah Seng Tay, GM and Head of Cloud and Developer Infrastructure at Airtable . “With Sentry providing accurate and diagnosable alerts, we’re able to better triage incidents during deployment and decentralize our release process. This all results in our engineering teams being able to ship code more efficiently and more frequently, while still keeping the quality of our service high."
“We ship a tremendous amount of code — eight deployments at the top of every hour — to launch new features. Combined with a highly distributed architecture, it was getting more and more complex for our teams to identify and fix errors and performance issues,” said Eviathar Moussaffi, Group Lead of Engineering at monday.com . “Providing the most optimal user experience to our customers is critical to the success of our business, and Sentry allows us to eliminate unnecessary noise and reduces the time to resolution, so our developers can be most effective. The demands on our business are only going to increase, and Sentry provides a way for our team to have a holistic view of the health of our applications.”
“The rate at which businesses are moving towards a digital-first mindset is unprecedented,” said Jay Simons , General Partner at BOND. “In order to sustain applications, programs, and mobile, the proper infrastructure needs to be in place to manage and monitor the health of every customer solution. For many businesses, an error in code or a performance issue in the final touchpoint with an end-user can mean the loss of a sale or customer.”
“The rate of software development is going to exponentially increase, and developers are seeking ways to quickly solve any issues that will affect the end-user experience,” said Dan Levine , Partner at Accel, a firm that has also invested in companies like Atlassian, CrowdStrike, Dropbox, PagerDuty, Qualtrics, and Slack. “With Sentry, companies can not only pinpoint the exact issue but also proactively monitor their application health. As we continue to see the move towards a digital-first world, Sentry is well-positioned to help companies, from small businesses to enterprises, ensure that they’re keeping up with customer expectations.”
To support growing demand, Sentry’s team has grown nearly 75% worldwide since this time last year, with plans to continue hiring for all offices, including a new hub opening in Europe. With this round of funding, Sentry will accelerate its go-to-market motion and teams, as the company expands on its product-led growth model and servicing its global customer base.
Learn more about Sentry’s plans for innovation and growth on the company blog .
About Sentry
For software teams, Sentry is essential for monitoring code health. From Error tracking to Performance Monitoring, developers can see clearer, solve quicker, and learn continuously about their applications — from frontend to backend. Loved by more than 3.5 million developers and 85,000 organizations worldwide, Sentry provides code-level observability to many of the world’s best-known companies like Disney, Peloton, Cloudflare, Eventbrite, Slack, Supercell, and Rockstar Games. Learn more at sentry.io or follow Sentry on GitHub , Twitter , Dribbble or LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005222/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom